Cache Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Cache Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Hold	10,143	–	–	0.11%	71
2026 Q1	$1.07M	Hold	10,143	–	–	0.12%	50
2025 Q4	$886K	Hold	10,143	–	–	0.11%	55
2025 Q3	$674K	Hold	10,143	–	–	0.12%	59
2025 Q2	$561K	Hold	10,143	–	–	0.15%	61
2025 Q1	$491K	Hold	10,143	–	–	0.19%	56
2024 Q4	$392K	Buy	+10,143	New	+$442K	0.16%	56

Other funds holding PTGX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Cache Advisors's PTGX Position: Q2 2026 in Review

Cache Advisors held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 10,143 shares worth $1.24M. The position accounts for 0.11% of the portfolio, ranked #71.

Cache Advisors first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 25 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Cache Advisors held 10,143 shares of Protagonist Therapeutics worth $1.24M as of Q2 2026.
Cache Advisors left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 0.11% of Cache Advisors's portfolio in Q2 2026, its #71 holding.
Cache Advisors first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
25 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Cache Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.